Patchy Chorioretinal Atrophy Changes at the Posterior Pole After Ranibizumab for Myopic Choroidal Neovascularization

Mariacristina Parravano, Fabio Scarinci, Marta Gilardi, Lea Querques, Monica Varano, Francesco Oddone, Francesco Bandello, Giuseppe Querques
2017 Investigative Ophthalmology and Visual Science  
Citation: Parravano M, Scarinci F, Gilardi M, et al. Patchy chorioretinal atrophy changes at the posterior pole after ranibizumab for myopic choroidal neovascularization. Invest Ophthalmol Vis Sci. 2017;58:6358-6364. PURPOSE. To investigate the potential role of ranibizumab treatment on the development or enlargement of chorioretinal atrophy (CRA) at the posterior pole in eyes with myopic choroidal neovascularization (mCNV). METHODS. This observational case series included patients having high
more » ... tients having high myopia spherical equivalent refractive error ‡ À6.00 diopters, axial length (AxL) ‡ 26.0 mm in both eyes, and mCNV treated with ranibizumab 0.5 mg in one eye, who were retrospectively enrolled. Areas of CRA in treated and fellow eyes were measured on fundus autofluorescence images at baseline, 12, and 24 months. The CRA hypoautofluorescent lesions were divided in two groups: perilesional atrophy, corresponding to area around the mCNV, and patchy extralesional atrophy, corresponding to CRA between the temporal vascular arcades. RESULTS. Thirty-six eyes of 18 patients were included. The mean perilesional CRA size significantly increased from baseline to 12 months (3.5 6 10.6 mm 2 , P ¼ 0.02) and 24 months (4.4 6 11.7 mm 2 , P ¼ 0.038) in the treated eye. In treated and not treated eyes, patchy extralesional CRA at the posterior pole increased significantly from baseline to 12 and 24 months follow-up. None of the fellow eyes developed mCNV. No significant relationship was found between the number of injections, AxL, age, and perilesional and patchy extralesional CRA in the treated and not treated eyes (P > 0.05). CONCLUSIONS. In eyes with pathologic myopia and mCNV, intravitreal injections of ranibizumab should not be considered as a contributing risk factor worsening the natural course of CRA, even though the risk of the perilesional CRA enlargement should be taken into account.
doi:10.1167/iovs.17-22633 pmid:29260192 fatcat:7khdfdznlndkxmaud5k67mfnry